W. Rathmell
Last active: 11/27/2019

High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.

Rathmell WK, Monk JP
Urology. 2008 72 (3): 659-63

PMID: 18649931 · DOI:10.1016/j.urology.2008.05.009

OBJECTIVES - Renal medullary carcinoma is a rare and highly aggressive cancer that is characteristically resistant to most forms of chemotherapy. This pediatric tumor, exclusively affecting individuals who carry at least one sickle hemoglobin allele, carries a uniformly fatal outcome, usually within a matter of weeks, and no effective therapies have been reported.

METHODS - We report on the use of a high-dose-intensity regimen of methotrexate, vinblastine, doxorubicin, and cisplatin in 3 patients.

RESULTS - All 3 patients were able to tolerate multiple cycles of therapy and achieved at least a partial response and longer survival than predicted from the historical precedent.

CONCLUSIONS - Our results have shown that this regimen provides a tolerable therapy with efficacy to promote survival for several months and suggest that highly intensive regimens of chemotherapy might bring additional benefit to the young patients with these rare tumors.

MeSH Terms (19)

Adolescent Adult Antineoplastic Combined Chemotherapy Protocols Carcinoma, Renal Cell Cisplatin Comorbidity Disease Progression Doxorubicin Female Humans Kidney Neoplasms Lymph Nodes Male Methotrexate Middle Aged Neoplasm Metastasis Sickle Cell Trait Treatment Outcome Vinblastine

Connections (1)

This publication is referenced by other Labnodes entities: